Inactive Instrument

Hemispherx BioPharma, Inc Stock price Nyse

Equities

US42366C3016

Biotechnology & Medical Research

Sales 2023 * 157K Sales 2024 * 70K Capitalization 21.64M
Net income 2023 * -22M Net income 2024 * -27M EV / Sales 2023 * 138 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 309 x
P/E ratio 2023 *
-0.98 x
P/E ratio 2024 *
-0.98 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 91.31%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Hemispherx BioPharma, Inc

Managers TitleAgeSince
Chief Executive Officer 72 08-11-16
Director of Finance/CFO 68 22-04-03
Chief Tech/Sci/R&D Officer - 22-05-31
Members of the board TitleAgeSince
Director/Board Member 66 23-03-27
Chairman 88 98-06-30
Chief Executive Officer 72 08-11-16
More insiders
AIM ImmunoTech Inc. is an immuno-pharmaceutical company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules and Alferon N Injection (Interferon Alfa-N3). Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS) and is an experimental drug in the United States undergoing clinical development for the treatment of certain cancers and ME/CFS. Alferon N Injection is the registered trademark for its injectable formulation of natural alpha interferon. Alferon N Injection is a natural-source, multi-species alpha interferon approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock AIM ImmunoTech Inc.
  4. Stock Hemispherx BioPharma, Inc - Nyse